Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Herbalife Nutrition Ltd (HLF) vs Heron Therapeutics Inc (HRTX) Price & Performance

Herbalife Nutrition LtdTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Herbalife Nutrition Ltd vs Heron Therapeutics Inc — how do they compare? Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: Herbalife Nutrition Ltd is far larger — about 20× Heron Therapeutics Inc's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HLFHRTX
Market Cap
$1.23B$61.47M
Sector
Consumer StaplesHealth
52-Week High
$19.96$1.49
52-Week Low
$7.75$0.32
Enterprise Value
$3.06B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Herbalife Nutrition Ltd

Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.

The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Herbalife Nutrition Ltd

Herbalife Nutrition Ltd is an international nutrition company.

Read more on HLF

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX